



How Prior Authorization is Innovating to Address Challenges

Fall 2024



Prior Authorization: A Process that Requires Providers to get Approval from Payors Before Providing Care Continues to Burden all Stakeholders by Affecting Patient Care and Increasing Costs

Prior authorization challenges are proactively being addressed by The Centers for Medicare & Medicaid Services (“CMS”), which recently issued the Interoperability and Prior Authorization Final Rule, along with emerging technology initiatives are aimed at improving efficiency and transparency

Prior authorization was established by payors to try and ensure that only medically necessary patient care is covered in a cost-effective manner. In conjunction with fee-for-service reimbursement payment models, providers were potentially incentivized to bill for as many medical services as possible, irrespective of delivering better outcomes in a cost-efficient manner. In order to evaluate whether or not care is medically necessary and otherwise covered, payors developed prior authorization standards based on medical guidelines, costs and utilization.

Patient Care Issues: The prior authorization process varies by payor but involves the submission of administrative and clinical information by the provider. In 2023, the American Medical Association surveyed over 1,000 practicing physicians, 94% of which reported that prior authorization delayed care at least “Sometimes” to “Always” and nearly one in four physicians (24%) reported that prior authorization led to a serious adverse event for a patient in their care⁽¹⁾.

Increased Costs: Prior authorization often leads to a significant administrative burden that has resulted in high amounts of physician burnout. In general, each payor has unique requirements for prior authorization submission and documentation. 30% of medical groups report having to interface with 11 or more health plan proprietary web portals, with 76% of medical groups interfacing with five or more proprietary portals⁽²⁾. The administrative strain takes providers away from patient care, while increasing costs to practices.


CMS Response: CMS recognized the adverse consequences related to prior authorization and is addressing it through its newly introduced Interoperability and Prior Authorization Final Rule (“Final Rule”) which was issued on January 17, 2024. The Final Rule is a requirement affecting a broad spectrum of payers and providers to simplify and streamline the prior authorization process, enabling providers to submit requests and receive prompt notifications about the status of these requests more efficiently. Impacted payors are required to implement the non-technical provisions by January 1, 2026 and application programming interfaces (“APIs”) by January 1, 2027. CMS’ implementation of the Final Rule may also result quicker and wider adoption among commercial payors.

Emerging Technology: A McKinsey & Company study estimated that 50% - 70% of manual prior authorization tasks can be automated. This presents a significant opportunity for technology, specifically artificial intelligence, to increase administrative efficiency through automating basic tasks and prior authorization decisions to accelerate care delivery to improve patient outcomes. In this regard, there are currently a number technology initiatives being developed and implemented.



(1) “2023 AMA prior authorization physician survey” American Medical Association, 2024

(2) “Spotlight: Prior Authorization in Medicare Advantage” MGMA, May 2023

Typical Prior Authorization Process Involves Multiple Administrative Tasks, Long Delays and Lack of Transparency



Current Challenges with Prior Authorization are Affecting Patients, Physicians and Adding Costs to the Healthcare System



Source: “2023 AMA prior authorization physician survey” American Medical Association, 2024

Interoperability and Prior Authorization Final Rule Overview

CMS issued The Final Rule to address challenges with prior authorization which impact patient, physician and overall healthcare costs

Payor / Provider Scope

The Final Rule covers both health plans and providers



Health Plans Covered

- Medicaid Children's Health Insurance Program
- Medicare Advantage
- Qualified Health Plans ("QHP") on Federally Facilitated Exchanges ("FFE")

Providers Covered

- Merit-based Incentive Payment System eligible clinicians under the Promoting Interoperability performance category
- Hospitals and critical access hospitals under the Medicare Promoting Interoperability Program

Note: Prescription drugs are not covered at this time

Data Standardization and APIs

Payors will implement Health Level 7 ("HL7") and Fast Healthcare Interoperability Resources ("FHIR") APIs that will standardize and improve electronic exchange of healthcare data



Patient Access API: Allows patients to access claims and clinical data through health application



Provider Access API: Allows providers access encounter data, medical services, adjudicated claims and prior authorizations



Payor-to-Payor API: Allows exchange of data between payors



Prior Authorization API: Automate prior authorization process (determination, if required, through submission and status tracking)

Prior Authorization Decisions



Timing

CMS has shortened the timeline for prior authorization decisions (except for QHPs & FFEs)

- Standard Decisions: 7 days
- Expedited Decisions: 3 days



Denials

Payors must provide detailed and specific reasons for prior authorization denials

- Providers will be able to take necessary actions to treat patients (e.g. appeal the denial or recommendation of alternative treatment)



Public Report of Metrics

Payors must report certain metrics on the prior authorization determinations on their public website on an annual basis



~\$15 Billion

CMS estimated savings for hospitals and doctor's offices over 10 years

"Together, these new requirements to prior authorization process will reduce administrative burden on the healthcare workforce, empower clinicians to spend more time providing direct care to their patients and prevent avoidable delays in care for patients" - CMS

Sources: Godavarthi, R. (2024, May 24). Key changes in the CMS Final Rule on Prior Authorization. MCG. https://www.mcg.com/blog/2024/05/29/cms-final-rule-prior-authorization-interoperability/?utm_medium=webinar&utm_source=on24&utm_campaign=wbr-in-2024-interop-series-2

Pestaina, K., Lo, J., Pollitz, K., & Wallace, R. (2024, July 30). Final prior authorization rules look to streamline the process, but issues remain. KFF. <https://www.kff.org/private-insurance/issue-brief/final-prior-authorization-rules-look-to-streamline-the-process-but-issues-remain/>

Emerging Technology in Prior Authorization

Technology is being developed and implemented to automate the prior authorization process

01 Current State of Prior Authorization



50-70%

Of manual tasks can be automated



High rate of manual decision making can lead to **inconsistent clinical determinations**



Rules are **continuously changing and requirements among payors are inconsistent, while lacking transparency** (different portals, submission requirements etc.)



Traditional prior authorization methods can **obstruct patient access and treatment**

02 Benefits of Technology



Streamline Processes

Automating tasks such as submission, tracking and communication which save time and reduce errors



Real-Time Guidance

Integration with clinician decision support tools can provide guidance to providers on eligibility and documentation requirements



Improved Communication

Portals and APIs can facilitate communication between providers, payors and patients, increasing transparency and encouraging collaboration



Actionable Insights

Data analytics can identify trends in prior authorization denials and inform strategies to reduce denials

03 Emerging Technology



Electronic Prior Authorization

Fully electronic transmission of prior authorization information between provider and payor can expedite the time from submission to decision making



Artificial Intelligence ("AI")



Machine Learning ("ML")

ML assesses data and identifies patterns based on historical outcomes to continuously learn from past decisions, improving accuracy and efficiency over time



Natural Language Processing ("NLP")

NLP can transform unstructured text (patient records, handwritten clinical documents etc.) to data formats that payors can use to facilitate quicker decisions



Optical Character Recognition ("OCR")

OCR is the process of digitizing into machine readable formats (e.g. faxes, pdfs) at intake to speed up and consolidate the prior authorization process

Key Considerations when Adopting Technology



Healthcare Vulnerable to Cyber Attacks

In Feb 2024, Change Healthcare suffered a cyber attack causing a backlog of prior authorization requests leading to disruptions in patient care and cash flow issues for providers



AI Can Lead to Inappropriate Denials

Complex decision making will still require human intervention. AI models can inherit biases based on historical data, potentially leading to erroneous denials









Integration into Current IT Ecosystem

Introducing new technology into current Healthcare IT infrastructure (workflow tools, EMRs etc.) can be complex and require significant resources

Sources: Al-Haque, S., Khanna, V., Mandal, S., Rayasam, M., & Singh, P. (2022, April 19). Ai ushers in next-gen prior authorization in Healthcare. McKinsey & Company. <https://www.mckinsey.com/industries/healthcare/our-insights/ai-ushers-in-next-gen-prior-authorization-in-healthcare>

Namasivayam, S. (2023, September 29). Ai is already transforming prior authorization: Employing more mature technologies as AI continues its evolution. Future Healthcare Today. <https://futurehealthcareday.com/ai-is-already-transforming-prior-authorization-employing-more-mature-technologies-as-ai-continues-its-evolution/>

Notable Prior Authorization Companies Leveraging Technology

						
Technology Overview	Uses generative AI (“GenAI”) and large language models (“LLMs”) to develop healthcare specific models by training them on clinical and financial data	Ingests and digitizes all prior authorization requests, then applies rules to automatically approve majority of requests based on medical guidelines and payor rules	SaaS-based platform automates (using GenAI and ML) patient access tasks associated with prior authorization, eligibility and benefits for both medical and pharmacy	The platform integrates with any EMR to connect directly with all insurance carriers to submit, monitor and complete prior authorization	Leverages AI to offer practices a cloud-based tool to submit, track and manage prior authorization	Speeds and simplifies prior authorization by automating submissions, status checking, verification, reporting, and EMR synchronization from one platform and portal
Founded	2018	2019	2015	2014	2018	2011
HQ	San Francisco, CA	Boston, MA	Mesa, AZ	Columbus, OH	San Francisco, CA	Huntington Beach, CA
Employees	199	700	52	65	53	65
Financing / Investor(s)	Series B: \$60M (Mar-21) Lead Investor: BOND Series A: \$20M (Nov-19) Lead Investor andreessen. horowitz	Series B2: \$50M (Feb-24) Lead Investor: None DEERFIELD Advancing Healthcare® Series B: \$36.1M (Apr-21) Lead Investor: polarispartners Series A: \$10M (Jul-20) Lead Investors: DEFINE VENTURES flare capital partners	Acquired by DrFirst in Apr-24 DrFirst Unite the Healthiverse™	\$25M funding round (Feb-22) for a total over \$57M of total funding Lead Investor: INSIGHT PARTNERS	Series B: \$17M (May-24) Lead Investor: QUESTA CAPITAL Series A: \$12M (Jun-22) Lead Investor: VIVECOLLECTIVE™ CLEARLAKE	Received capital investment from Hughes & Company (Apr-23) HUGHES & COMPANY

Select Kroll Healthcare Transaction Experience

<p>SELL-SIDE ADVISOR</p> <p>CABLES AND SENSORS</p> <p>has been acquired by</p> <p>PARTSOURCE</p> <p>a portfolio company of</p> <p>BainCapital PRIVATE EQUITY</p>	<p>SELL-SIDE ADVISOR</p> <p>AQREVA DRS</p> <p>has been acquired by</p> <p>unislink</p> <p>a portfolio company of</p> <p>Riverside PARTNERS</p>	<p>SELL-SIDE ADVISOR</p> <p>TRI-AD</p> <p>has been acquired by</p> <p>navia</p> <p>a portfolio company of</p> <p>TA ASSOCIATES SHORE Capital Partners</p>	<p>SELL-SIDE ADVISOR</p> <p>LSL</p> <p>has been acquired by</p> <p>Fifth Century Partners</p>	<p>SELL-SIDE ADVISOR</p> <p>MEDI WEIGHTLOSS The one that works!</p> <p>has been acquired by</p> <p>Audax Private Equity</p>	<p>SELL-SIDE ADVISOR</p> <p>RSA</p> <p>has been acquired by</p> <p>SHERIDAN CAPITAL PARTNERS</p>
<p>SELL-SIDE ADVISOR</p> <p>NXC IMAGING</p> <p>has been acquired by</p> <p>Canon</p>	<p>SELL-SIDE ADVISOR</p> <p>CCARE</p> <p>has been acquired by</p> <p>INTEGRATED ONCOLOGY NETWORK</p> <p>a portfolio company of</p> <p>SILVER OAK SERVICES PARTNERS</p>	<p>SELL-SIDE ADVISOR</p> <p>Allentown.</p> <p>has been acquired by</p> <p>Aterian INVESTMENT PARTNERS</p>	<p>SELL-SIDE ADVISOR</p> <p>TheraOffice</p> <p>has been acquired by</p> <p>Netsmart</p> <p>a portfolio company of</p> <p>TA ASSOCIATES GI PARTNERS</p>	<p>SELL-SIDE ADVISOR</p> <p>AS Software</p> <p>has been acquired by</p> <p>AEA GROWTH</p>	<p>SELL-SIDE ADVISOR</p> <p>Universal Spine & Joint Specialists</p> <p>has been acquired by</p> <p>SURGERY PARTNERS</p>
<p>SELL-SIDE ADVISOR</p> <p>Insignia Health</p> <p>has been acquired by</p> <p>Phresia</p>	<p>SELL-SIDE ADVISOR</p> <p>lab products harford systems inc</p> <p>Subsidiaries of ShoreView Industries' Portfolio Company</p> <p>AVIDITY SCIENCE</p> <p>has been acquired by</p> <p>GENCAP AMERICA</p>	<p>SELL-SIDE ADVISOR</p> <p>SGR MEDICAL TRANSPORTATION</p> <p>has been acquired by</p> <p>BEACON MOBILITY</p> <p>a portfolio company of</p> <p>Audax Private Equity</p>	<p>SELL-SIDE ADVISOR</p> <p>STRIVE DENTAL MANAGEMENT</p> <p>has been acquired by</p> <p>APEX DENTAL PARTNERS</p> <p>a portfolio company of</p> <p>ENDEAVOUR</p>	<p>SELL-SIDE ADVISOR</p> <p>The Wellness NETWORK</p> <p>a portfolio company of</p> <p>GRANITE BRIDGE PARTNERS</p> <p>has been acquired by</p> <p>WebMD</p>	<p>SELL-SIDE ADVISOR</p> <p>The Difference Card</p> <p>a portfolio company of</p> <p>FLORIN</p> <p>has been acquired by</p> <p>NCP NORTHLANE CAPITAL PARTNERS</p>



For more information, please contact:



Eric Coburn
Managing Director
Head of Healthcare Investment Banking
+1 917 692 6283
eric.coburn@kroll.com



Nick Konstantinou
Managing Director
Chicago
+1 216 543 7885
nickkonstantinou@kroll.com



Michael Weber
Managing Director
Chicago
+1 804 543 1438
michael.weber@kroll.com



Peter Machmeier
Director
Chicago
+1 612 849 3792
peter.machmeier@kroll.com



Cray Yoo
Vice President
Los Angeles
+1 310 498 2500
cray.yoo@kroll.com



Eric Barker
Vice President
Los Angeles
+1 408 375 0612
eric.barker@kroll.com

About Kroll

As the leading independent provider of risk and financial advisory solutions, Kroll leverages our unique insights, data and technology to help clients stay ahead of complex demands. Kroll's global team continues the firm's nearly 100-year history of trusted expertise spanning risk, governance, transactions and valuation. Our advanced solutions and intelligence provide clients the foresight they need to create an enduring competitive advantage. At Kroll, our values define who we are and how we partner with clients and communities. Learn more at www.kroll.com.

M&A advisory, capital raising and secondary market advisory services in the United States are provided by Kroll Securities, LLC (member FINRA/SIPC). M&A advisory, capital raising and secondary market advisory services in the United Kingdom are provided by Kroll Securities Ltd., which is authorized and regulated by the Financial Conduct Authority (FCA). Valuation Advisory Services in India are provided by Kroll Advisory Private Limited (formerly, Duff & Phelps India Private Limited), under a category 1 merchant banker license issued by the Securities and Exchange Board of India.